Aquaporin-4 antibody–negative neuromyelitis optica
Authors:
- Romain MarignierRMRomain Marignier
- Raphaël Bernard-ValnetRBRaphaël Bernard-Valnet
- Pascale GiraudonPGPascale Giraudon
- Nicolas CollonguesNCNicolas Collongues
- Caroline PapeixCPCaroline Papeix
- Hélène ZéphirHZHélène Zéphir
- Gaëlle CavillonGCGaëlle Cavillon
- Véronique RogemondVRVéronique Rogemond
- Romain CaseyRCRomain Casey
- Bernard FrangoulisBFBernard Frangoulis
- Jérôme De SèzeJSJérôme De Sèze
- Sandra VukusicSVSandra Vukusic
- 11 June 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (24) , 2194-2200
Abstract
Objective: To optimize aquaporin-4 (AQP4) antibody (Ab) detection and to assess the influence of the increased sensitivity of the assay on the demographic and disease-related characteristics of a group of AQP4-Ab–negative patients. Methods: Serum samples were obtained from patients included in the French NOMADMUS database with a definite diagnosis of neuromyelitis optica (NMO) (n = 87) and were compared with controls (n = 54). They were tested by indirect immunofluorescence and cell-based assays (CBAs) in various conditions and with several plasmids. Results: We identified the CBA on live cells transfected with the untagged AQP4-M23 isoform as the best method, with a sensitivity of 74.4% and a specificity of 100%. We demonstrated a direct relationship between improvement of the sensitivity of the detection method and the distinctiveness and characteristics of the AQP4-Ab–negative NMO group. Whereas with the classic indirect immunofluorescence or current AQP4-M1 CBA we found only slight differences between the 2 populations, using the AQP4-M23 CBA, we demonstrated that patients with AQP4-Ab–negative NMO expressed specific demographic and disease-related features. They were characterized by an equal male/female ratio (p < 0.001), a Caucasian ethnicity (p = 0.029), and an overrepresentation of simultaneous optic neuritis and transverse myelitis at first episode (p = 0.015). In terms of disability, they experienced a better visual acuity at last follow-up compared with seropositive NMO (p = 0.007). Conclusion: This raises the question of a distinct physiopathology for patients with AQP4-Ab–negative NMO and of their place in the spectrum of the disease.Keywords
This publication has 35 references indexed in Scilit:
- Anti–Aquaporin‐4 monoclonal antibody blocker therapy for neuromyelitis opticaAnnals of Neurology, 2011
- Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injuryBrain, 2010
- Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigenJournal of the Neurological Sciences, 2010
- Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivoAnnals of Neurology, 2009
- Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse MyelitisArchives of Neurology, 2008
- NMO-IgG and Devic's neuromyelitis optica: a French experienceMultiple Sclerosis Journal, 2008
- The spectrum of neuromyelitis opticaThe Lancet Neurology, 2007
- NMO-IgG in the diagnosis of neuromyelitis opticaNeurology, 2007
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004